Symbiotec Pharmalab Q1FY27 Call Set for Sep 22

What the company has announced

Symbiotec Pharmalab Ltd has informed the exchanges that it will hold an earnings conference call to discuss its financial performance and business updates for the quarter ended June 30, 2026 (Q1FY27). The call is scheduled for Tuesday, September 22, 2026 at 10:00 AM IST and will be conducted through a virtual or audio conference. The event is being hosted by JM Financial Institutional Securities Limited. The company stated that the schedule is subject to change due to exigencies. It also indicated that no unpublished price sensitive information will be shared during the call.

Board meeting to approve Q1FY27 financial results

Ahead of the call, Symbiotec Pharmalab disclosed that its Board of Directors meeting was scheduled on September 21, 2026. The agenda includes considering and approving unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The company also referred to the Limited Review Report that would accompany these results. This sequence, board approval followed by an analyst and investor interaction, is commonly used to ensure that discussion is anchored to published financial disclosures. The company filed the call intimation under Regulation 30 of the Listing Obligations and Disclosure Requirements (LODR).

Earnings call details shared with investors

The company’s filing includes dial-in details for participants. Investors and analysts can join the call using the universal dial-in numbers +91 22 6280 1366 or +91 22 7115 8267. The intent of the call is to discuss financial performance for the quarter and share business updates, as per the intimation. The conference call is positioned as an analyst and investor meet, which typically allows stakeholders to ask questions on reported numbers and operating trends. The filing also notes that the detailed invitation with call particulars was enclosed.

Stock price context around the disclosure

Alongside the corporate-action style summary shared in the provided data, Symbiotec Pharmalab’s last traded price (LTP) was shown in relation to the quarterly result announcement date. The LTP at announcement was listed at ₹1,138.05 on September 21, 2026. The LTP at record day was listed at ₹1,095.10. Separately, the stock price was also stated as ₹1,095.10 as of September 21, 2026, with a previous close of ₹1,095.10.

Snapshot of quarterly financial performance (₹ crore)

The provided financial tables include quarterly metrics that put the company’s profitability in context. For the quarter shown as Jun 2025 in one table, revenue is listed at ₹206 crore, expenses at ₹145 crore, and EBITDA at ₹61 crore. The same snapshot shows operating profit margin at 29%, depreciation at ₹11 crore, interest at ₹5 crore, profit before tax at ₹45 crore, tax at ₹15 crore, and net profit at ₹30 crore. A separate earnings table for “Q1 FY25-26” lists total revenue at ₹203.17 crore and net profit at ₹29.92 crore, indicating a similar scale of quarterly performance. All figures in the tables are in ₹ crore, except per-share values.

Earnings table shows Q1 and full-year figures

The earnings table shared in the content provides a structured view of revenue, costs, and profit measures. For Q1 FY25-26, it lists total revenue of ₹203.17 crore and expenses of ₹145.21 crore. Operating profit is shown at ₹57.96 crore, with depreciation at ₹10.51 crore and interest at ₹5.28 crore. Profit before tax is listed at ₹44.82 crore, tax at ₹14.90 crore, and net profit at ₹29.92 crore. The same table also provides FY25-26 totals including total revenue of ₹869.15 crore and net profit of ₹109.90 crore, with FY24-25 comparison values shown as ₹751.55 crore revenue and ₹96.79 crore net profit.

Key facts table

Longer-term financial history included in the dataset

The content also includes a multi-year profit and loss series (Mar 2020 to Mar 2024) showing net sales and profitability over time. Net sales are listed at ₹531.19 crore in Mar 2020, ₹622.86 crore in Mar 2021, ₹633.85 crore in Mar 2022, ₹563.59 crore in Mar 2023, and ₹673.61 crore in Mar 2024. The same table shows net profit at ₹72.52 crore (Mar 2020), ₹135.56 crore (Mar 2021), ₹61.73 crore (Mar 2022), -₹22.66 crore (Mar 2023), and ₹88.95 crore (Mar 2024). It also shows an exceptional item of -₹64.57 crore in Mar 2023, which aligns with the reported loss in that year.

Company profile details disclosed

The dataset includes Symbiotec Pharmalab’s address details as 385/2, Pigdamber, Rau, Mhow, Indore, Madhya Pradesh, 453331. It lists the company website as http://www.symbiotec.com and the email as secretarial@symbiotec.com. In the management section shown, Anil Satwani is listed as Chairman and Managing Director. These details are typically included in company profiles and are relevant for investors tracking filings and corporate communications.

Why this event matters for tracking results

For market participants, the combination of a scheduled board meeting to approve unaudited results and a follow-up earnings call helps structure information flow. The board meeting indicates when results are expected to be finalised for release, while the call provides a forum to clarify reported line items such as revenue, expenses, operating profit, and tax. The company’s statement about not sharing unpublished price sensitive information sets guardrails for the discussion. The next concrete milestone in the timeline is the scheduled earnings conference call on September 22, 2026.